[Open clinical testing of 7-chlor-1-(cyclopropylmethyl)-1, 3-dihydro-5 phenyl-2H-1, 4 benzodiazepine-2-one(Prazepam) in the indication as tranquilizing and antispastic agent].
D000328:Adult; D000368:Aged; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004285:Dogs; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009120:Muscle Cramp / Q000188:drug therapy; D009128:Muscle Spasticity / Q000188:drug therapy*; D019965:Neurocognitive Disorders / Q000188:drug therapy; D009497:Neurotic Disorders / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use; D010554:Personality Disorders / Q000188:drug therapy; D011222:Prazepam / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000627:therapeutic use
D010276:Parasympatholytics; D014149:Tranquilizing Agents; D011222:Prazepam
Offene klinische Prüfung von 7-Chlor-1-(Cyclopropylmethyl)-1,3-dihydro-5 phenyl-2H-1,4 benzodiazepin-2-on (Prazepam) in der Indikation als Tranquilizer und Antispastikum.